Illumina has released its RefSet line of oligos designed for human gene-expression microarrays, the company said Feb. 5.
At a cost of $39,000 per set, the RefSet product contains 22,740 70-mer oligo probes targeting 20,726 genes detailed in the National Center for Biotechnology Information Human Reference Sequence database. Sets also include a subset of probes designed to interrogate alternative splice variants of more than 1,300 genes that express multiple mRNA isoforms.
Sequence information for the new set, which Illumina said represents “the first of a series of standard product offerings” in its Oligator line, will be “fully disclosed and freely available.”
German genotyping company Ingenium Pharmaceuticals said Feb. 3 it will use a murine-tissue archive held by its country’s National Research Center for Environment and Health.
Munich-based Ingenium said it will use the archive in its Ingenotyping platform, which the company said is a novel way of producing murine models with “subtle gene alterations” for use in drug discovery and development. The expansion doubles Ingenium’s archive, the firm added.
The Ingenotyping technology is a second-generation tool for the in-vivo validation of drug targets. The platform is designed to provide a series of mammalian models that carry unique genetic alterations in any gene of interest. It is enabled by Ingenium’s murine-tissue archive.
Promega and CropDesign have partnered to launch an ultra-high-throughput plant genome-purification method that uses Promega’s Wizard technology, Promega said Feb. 5.
The method uses undisclosed high-throughput protocols developed by Belgium-based CropDesign, which also relied on tools robotics designed by Tecan.
Promega, which is headquartered in Madison, Wis., said the protocol uses a method that can process 24 plates in 24 hours on a Tecan Genesis system. The protocol, which will be sold to researchers internationally.